title: [Metabolic disturbances as a factor of the pathogenesis of hypertensive disease and its clinical outcomes].
abstract: OBJECTIVE
  To identify and determine the mechanisms of an association between arterial hypertension (AH) and proatherogenic systemic metabolic disturbances in hypertensive disease (HD), as well as the possibility of eliminating these disturbances by antihypertensivetherapy.
  
  
  METHODS
  Fifty-four patients with HD and 64 persons randomly selected from an unorganized urban population were examined. Systolic and diastolic blood pressure (BP), insulin sensitivity, the most important metabolic parameters of lipids, lipoproteins, and glucose, the degree of systemic inflammation and oxidative stress, and the rate of lipoprotein proatherogenic and immunogenic modification were determined.
  
  
  RESULTS
  All the patients with HD were found to have a regular concurrence of AH with systemic inflammation and activated free-radical reactions, metabolic abnormalities, such as atherogenic dyslipidemia, insulin resistance, atherogenic and immunogenic modified lipoproteins. Antihypertensive treatment failed to eliminate metabolic disturbances even when BP control was fully restored.
  
  
  CONCLUSIONS
  AH and systemic metabolic disturbances in HD have a common pathogenetic basis and the treatment of hypertensive patients should provide the normalization of not only BP, but also inflammatory and oxidative status and systemic metabolism.
authors.forename: V N
authors.initials: VN
authors.lastname: Kovalenko
authors.forename: T V
authors.initials: TV
authors.lastname: Talayeva
authors.forename: V A
authors.initials: VA
authors.lastname: Shumakov
authors.forename: V V
authors.initials: VV
authors.lastname: Bratus
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D016022:Case-Control Studies; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D007249:Inflammation / Q000503:physiopathology; D007333:Insulin Resistance; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000378:metabolism; D008659:Metabolic Diseases / Q000209:etiology / Q000503:physiopathology*; D018384:Oxidative Stress; D016896:Treatment Outcome
chemical_list: D000959:Antihypertensive Agents; D001786:Blood Glucose; D008055:Lipids; D008074:Lipoproteins